Cancer risk in primary sclerosing cholangitis: Epidemiology,prevention, and surveillance strategies
|
摘要
Primary sclerosing cholangitis(PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra-and/or extrahepatic biliary ducts. While its features and disease course can be variable,most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly,PSC is associated with a significantly increased risk of malignancy compared to the general population, mainly cholangiocarcinoma, gallbladder carcinoma,hepatocellular carcinoma, and colorectal cancer, with nearly 50% of deaths in patients with PSC being due to cancer. Therefore, robust surveillance strategies are needed, though uncertainty remains regarding how to best do so. In this review, we discuss the epidemiology, prevention, and surveillance of cancers in patients with PSC. Where evidence is limited, we present pragmatic approaches based on currently available data and expert opinion.
Primary sclerosing cholangitis(PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra-and/or extrahepatic biliary ducts. While its features and disease course can be variable,most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly,PSC is associated with a significantly increased risk of malignancy compared to the general population, mainly cholangiocarcinoma, gallbladder carcinoma,hepatocellular carcinoma, and colorectal cancer, with nearly 50% of deaths in patients with PSC being due to cancer. Therefore, robust surveillance strategies are needed, though uncertainty remains regarding how to best do so. In this review, we discuss the epidemiology, prevention, and surveillance of cancers in patients with PSC. Where evidence is limited, we present pragmatic approaches based on currently available data and expert opinion.
Primary sclerosing cholangitis(PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra-and/or extrahepatic biliary ducts. While its features and disease course can be variable,most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly,PSC is associated with a significantly increased risk of malignancy compared to the general population, mainly cholangiocarcinoma, gallbladder carcinoma,hepatocellular carcinoma, and colorectal cancer, with nearly 50% of deaths in patients with PSC being due to cancer. Therefore, robust surveillance strategies are needed, though uncertainty remains regarding how to best do so. In this review, we discuss the epidemiology, prevention, and surveillance of cancers in patients with PSC. Where evidence is limited, we present pragmatic approaches based on currently available data and expert opinion.
引文
1 Lazaridis KN,LaRusso NF.Primary Sclerosing Cholangitis.N Engl J Med 2016;375:1161-1170[PMID:27653566 DOI:10.1056/NEJMra1506330]
2 Tabibian JH,Lindor KD.Primary sclerosing cholangitis:A review and update on therapeutic developments.Expert Rev Gastroenterol Hepatol 2013;7:103-114[PMID:23363260 DOI:10.1586/egh.12.80]
3 O’Hara SP,Tabibian JH,Splinter PL,LaRusso NF.The dynamic biliary epithelia:Molecules,pathways,and disease.J Hepatol 2013;58:575-582[PMID:23085249 DOI:10.1016/j.jhep.2012.10.011]
4 Porayko MK,Wiesner RH,LaRusso NF,Ludwig J,MacCarty RL,Steiner BL,Twomey CK,Zinsmeister AR.Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease.Gastroenterology 1990;98:1594-1602[PMID:2338198 DOI:10.1016/0016-5085(90)91096-O]
5 Boonstra K,Weersma RK,van Erpecum KJ,Rauws EA,Spanier BW,Poen AC,van Nieuwkerk KM,Drenth JP,Witteman BJ,Tuynman HA,Naber AH,Kingma PJ,van Buuren HR,van Hoek B,Vleggaar FP,van Geloven N,Beuers U,Ponsioen CY;EpiPSCPBC Study Group.Population-based epidemiology,malignancy risk,and outcome of primary sclerosing cholangitis.Hepatology 2013;58:2045-2055[PMID:23775876 DOI:10.1002/hep.26565]
6 Takakura WR,Tabibian JH,Bowlus CL.The evolution of natural history of primary sclerosing cholangitis.Curr Opin Gastroenterol 2017;33:71-77[PMID:28030370 DOI:10.1097/MOG.0000000000000333]
7 Boonstra K,Beuers U,Ponsioen CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:A systematic review.J Hepatol 2012;56:1181-1188[PMID:22245904 DOI:10.1016/j.jhep.2011.10.025]
8 Molodecky NA,Kareemi H,Parab R,Barkema HW,Quan H,Myers RP,Kaplan GG.Incidence of primary sclerosing cholangitis:A systematic review and meta-analysis.Hepatology 2011;53:1590-1599[PMID:21351115 DOI:10.1002/hep.24247]
9 Tsaitas C,Semertzidou A,Sinakos E.Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.World J Hepatol 2014;6:178-187[PMID:24799986 DOI:10.4254/wjh.v6.i4.178]
10 Silveira MG,Mendes FD,Diehl NN,Enders FT,Lindor KD.Thyroid dysfunction in primary biliary cirrhosis,primary sclerosing cholangitis and non-alcoholic fatty liver disease.Liver Int 2009;29:1094-1100[PMID:19291181 DOI:10.1111/j.1478-3231.2009.02003.x]
11 Lamberts LE,Janse M,Haagsma EB,van den Berg AP,Weersma RK.Immune-mediated diseases in primary sclerosing cholangitis.Dig Liver Dis 2011;43:802-806[PMID:21700515 DOI:10.1016/j.dld.2011.05.009]
12 Rupp C,Mummelthei A,Sauer P,Weiss KH,Schirmacher P,Stiehl A,Stremmel W,Gotthardt DN.NonIBD immunological diseases are a risk factor for reduced survival in PSC.Liver Int 2013;33:86-93[PMID:23157607 DOI:10.1111/liv.12028]
13 Folseraas T,Boberg KM.Cancer Risk and Surveillance in Primary Sclerosing Cholangitis.Clin Liver Dis2016;20:79-98[PMID:26593292 DOI:10.1016/j.cld.2015.08.014]
14 Gulamhusein AF,Eaton JE,Tabibian JH,Atkinson EJ,Juran BD,Lazaridis KN.Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.Am J Gastroenterol 2016;111:705-711[PMID:27002801 DOI:10.1038/ajg.2016.55]
15 Bergquist A,Ekbom A,Olsson R,Kornfeldt D,L??f L,Danielsson A,Hultcrantz R,Lindgren S,Prytz H,Sandberg-Gertzén H,Almer S,Granath F,BrooméU.Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.J Hepatol 2002;36:321-327[PMID:11867174 DOI:10.1016/S0168-8278(01)00288-4]
16 Claessen MM,Vleggaar FP,Tytgat KM,Siersema PD,van Buuren HR.High lifetime risk of cancer in primary sclerosing cholangitis.J Hepatol 2009;50:158-164[PMID:19012991 DOI:10.1016/j.jhep.2008.08.013]
17 Card TR,Solaymani-Dodaran M,West J.Incidence and mortality of primary sclerosing cholangitis in the UK:A population-based cohort study.J Hepatol 2008;48:939-944[PMID:18433916 DOI:10.1016/j.jhep.2008.02.017]
18 Zheng HH,Jiang XL.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease:A meta-analysis of 16 observational studies.Eur J Gastroenterol Hepatol 2016;28:383-390[PMID:26938805 DOI:10.1097/MEG.0000000000000576]
19 Said K,Glaumann H,Bergquist A.Gallbladder disease in patients with primary sclerosing cholangitis.JHepatol 2008;48:598-605[PMID:18222013 DOI:10.1016/j.jhep.2007.11.019]
20 Fevery J,Verslype C,Lai G,Aerts R,Van Steenbergen W.Incidence,diagnosis,and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.Dig Dis Sci 2007;52:3123-3135[PMID:17431781 DOI:10.1007/s10620-006-9681-4]
21 Weismüller TJ,Trivedi PJ,Bergquist A,Imam M,Lenzen H,Ponsioen CY,Holm K,Gotthardt D,F?rkkil?MA,Marschall HU,Thorburn D,Weersma RK,Fevery J,Mueller T,Chazouillères O,Schulze K,Lazaridis KN,Almer S,Pereira SP,Levy C,Mason A,Naess S,Bowlus CL,Floreani A,Halilbasic E,Yimam KK,Milkiewicz P,Beuers U,Huynh DK,Pares A,Manser CN,Dalekos GN,Eksteen B,Invernizzi P,Berg CP,Kirchner GI,Sarrazin C,Zimmer V,Fabris L,Braun F,Marzioni M,Juran BD,Said K,Rupp C,Jokelainen K,Benito de Valle M,Saffioti F,Cheung A,Trauner M,Schramm C,Chapman RW,Karlsen TH,Schrumpf E,Strassburg CP,Manns MP,Lindor KD,Hirschfield GM,Hansen BE,Boberg KM;International PSC Study Group.Patient Age,Sex,and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.Gastroenterology 2017;152:1975-1984.e8[PMID:28274849 DOI:10.1053/j.gastro.2017.02.038]
22 Burak K,Angulo P,Pasha TM,Egan K,Petz J,Lindor KD.Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.Am J Gastroenterol 2004;99:523-526[PMID:15056096 DOI:10.1111/j.1572-0241.2004.04067.x]
23 Ahrendt SA,Pitt HA,Nakeeb A,Klein AS,Lillemoe KD,Kalloo AN,Cameron JL.Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.J Gastrointest Surg 1999;3:357-67;discussion 367-8[PMID:10482687 DOI:10.1016/S1091-255X(99)80051-1]
24 Blechacz B.Cholangiocarcinoma:Current Knowledge and New Developments.Gut Liver 2017;11:13-26[PMID:27928095 DOI:10.5009/gnl15568]
25 Bergquist A,Glaumann H,Persson B,BrooméU.Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis:A case-control study.Hepatology 1998;27:311-316[PMID:9462625 DOI:10.1002/hep.510270201]
26 Ghouri YA,Mian I,Blechacz B.Cancer review:Cholangiocarcinoma.J Carcinog 2015;14:1[PMID:25788866 DOI:10.4103/1477-3163.151940]
27 Chapman MH,Webster GJ,Bannoo S,Johnson GJ,Wittmann J,Pereira SP.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis:A 25-year single-centre experience.Eur J Gastroenterol Hepatol 2012;24:1051-1058[PMID:22653260 DOI:10.1097/MEG.0b013e3283554bbf]
28 DeOliveira ML,Cunningham SC,Cameron JL,Kamangar F,Winter JM,Lillemoe KD,Choti MA,Yeo CJ,Schulick RD.Cholangiocarcinoma:Thirty-one-year experience with 564 patients at a single institution.Ann Surg 2007;245:755-762[PMID:17457168 DOI:10.1097/01.sla.0000251366.62632.d3]
29 Lee WJ,Lim HK,Jang KM,Kim SH,Lee SJ,Lim JH,Choo IW.Radiologic spectrum of cholangiocarcinoma:emphasis on unusual manifestations and differential diagnoses.Radiographics 2001;21 Spec No:S97-S116[PMID:11598251 DOI:10.1148/radiographics.21.suppl_1.g01oc12s97]
30 Fevery J,Verslype C.An update on cholangiocarcinoma associated with primary sclerosing cholangitis.Curr Opin Gastroenterol 2010;26:236-245[PMID:20216413 DOI:10.1097/MOG.0b013e328337b311]
31 Karlsen TH,Folseraas T,Thorburn D,Vesterhus M.Primary sclerosing cholangitis-a comprehensive review.J Hepatol 2017;67:1298-1323[PMID:28802875 DOI:10.1016/j.jhep.2017.07.022]
32 Hilscher MB,Tabibian JH,Carey EJ,Gostout CJ,Lindor KD.Dominant strictures in primary sclerosing cholangitis:A multicenter survey of clinical definitions and practices.Hepatol Commun 2018;2:836-844[PMID:30027141 DOI:10.1002/hep4.1194]
33 Lazaridis KN,Gores GJ.Primary sclerosing cholangitis and cholangiocarcinoma.Semin Liver Dis 2006;26:42-51[PMID:16496232 DOI:10.1055/s-2006-933562]
34 Mouchli MA,Singh S,Loftus EV,Boardman L,Talwalkar J,Rosen CB,Heimbach JK,Wiesner RH,Hasan B,Poterucha JJ,Kymberly WD.Risk Factors and Outcomes of De Novo Cancers(Excluding Nonmelanoma Skin Cancer)After Liver Transplantation for Primary Sclerosing Cholangitis.Transplantation 2017;101:1859-1866[PMID:28272287 DOI:10.1097/TP.0000000000001725]
35 Khorsandi SE,Salvans S,Zen Y,Agarwal K,Jassem W,Heaton N.Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation.Transpl Int 2011;24:e93-e96[PMID:21884553 DOI:10.1111/j.1432-2277.2011.01324.x]
36 Watt KD,Pedersen RA,Kremers WK,Heimbach JK,Sanchez W,Gores GJ.Long-term probability of and mortality from de novo malignancy after liver transplantation.Gastroenterology 2009;137:2010-2017[PMID:19766646 DOI:10.1053/j.gastro.2009.08.070]
37 Landaverde C,Ng V,Sato A,Tabibian J,Durazo F,Busuttil R.De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis.Ann Hepatol 2009;8:379-383[PMID:20009140 DOI:10.1152/ajpgi.90631.2008]
38 Heneghan MA,Tuttle-Newhall JE,Suhocki PV,Muir AJ,Morse M,Bornstein JD,Sylvestre PB,Collins B,Kuo PC,Rockey DC.De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant.Am J Transplant 2003;3:634-638[PMID:12752322 DOI:10.1034/j.1600-6143.2003.00110.x]
39 Tabibian JH,Bowlus CL.Primary sclerosing cholangitis:A review and update.Liver Res 2017;1:221-230[PMID:29977644 DOI:10.1016/j.livres.2017.12.002]
40 Tabibian J,Lazaridis K,LaRusso N,Jarnagin W.Primary Sclerosing Cholangitis.Jarnagin W.Blumgart’s Surgery of the Liver,Biliary Tract and Pancreas.Philadelphia,PA,United States:Elsevier;2017;663-674
41 Karlsen TH,Schrumpf E,Boberg KM.Gallbladder polyps in primary sclerosing cholangitis:Not so benign.Curr Opin Gastroenterol 2008;24:395-399[PMID:18408471 DOI:10.1097/MOG.0b013e3282f5727a]
42 Buckles DC,Lindor KD,Larusso NF,Petrovic LM,Gores GJ.In primary sclerosing cholangitis,gallbladder polyps are frequently malignant.Am J Gastroenterol 2002;97:1138-1142[PMID:12014717DOI:10.1111/j.1572-0241.2002.05677.x]
43 Sandrasegaran K,Menias CO.Imaging and Screening of Cancer of the Gallbladder and Bile Ducts.Radiol Clin North Am 2017;55:1211-1222[PMID:28991561 DOI:10.1016/j.rcl.2017.06.005]
44 Chapman R,Fevery J,Kalloo A,Nagorney DM,Boberg KM,Shneider B,Gores GJ;American Association for the Study of Liver Diseases.Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010;51:660-678[PMID:20101749 DOI:10.1002/hep.23294]
45 European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of cholestatic liver diseases.J Hepatol 2009;51:237-267[PMID:19501929 DOI:10.1016/j.jhep.2009.04.009]
46 Lindor KD,Kowdley KV,Harrison ME;American College of Gastroenterology.ACG Clinical Guideline:Primary Sclerosing Cholangitis.Am J Gastroenterol 2015;110:646-59;quiz 660[PMID:25869391 DOI:10.1038/ajg.2015.112]
47 Eaton JE,Thackeray EW,Lindor KD.Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis.Am J Gastroenterol 2012;107:431-439[PMID:22031356 DOI:10.1038/ajg.2011.361]
48 Razumilava N,Gores GJ,Lindor KD.Cancer surveillance in patients with primary sclerosing cholangitis.Hepatology 2011;54:1842-1852[PMID:21793028 DOI:10.1002/hep.24570]
49 Harnois DM,Gores GJ,Ludwig J,Steers JL,LaRusso NF,Wiesner RH.Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?J Hepatol 1997;27:512-516[PMID:9314129 DOI:10.1016/S0168-8278(97)80356-X]
50 Leidenius M,H?ckersted K,BrooméU,Ericzon BG,Friman S,Olausson M,Schrumpf E.Hepatobiliary carcinoma in primary sclerosing cholangitis:A case control study.J Hepatol 2001;34:792-798[PMID:11451160 DOI:10.1016/S0168-8278(01)00042-3]
51 Ali AH,Tabibian JH,Nasser-Ghodsi N,Lennon RJ,DeLeon T,Borad MJ,Hilscher M,Silveira MG,Carey EJ,Lindor KD.Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.Hepatology 2018;67:2338-2351[PMID:29244227 DOI:10.1002/hep.29730]
52 Francescone R,Hou V,Grivennikov SI.Cytokines,IBD,and colitis-associated cancer.Inflamm Bowel Dis 2015;21:409-418[PMID:25563695 DOI:10.1097/MIB.0000000000000236]
53 de Vries AB,Janse M,Blokzijl H,Weersma RK.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol 2015;21:1956-1971[PMID:25684965 DOI:10.3748/wjg.v21.i6.1956]
54 Loftus EV,Harewood GC,Loftus CG,Tremaine WJ,Harmsen WS,Zinsmeister AR,Jewell DA,Sandborn WJ.PSC-IBD:A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.Gut 2005;54:91-96[PMID:15591511 DOI:10.1136/gut.2004.046615]
55 BrooméU,L?fberg R,Veress B,Eriksson LS.Primary sclerosing cholangitis and ulcerative colitis:Evidence for increased neoplastic potential.Hepatology 1995;22:1404-1408[PMID:7590655 DOI:10.1002/hep.1840220511]
56 Soetikno RM,Lin OS,Heidenreich PA,Young HS,Blackstone MO.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis:A meta-analysis.Gastrointest Endosc2002;56:48-54[PMID:12085034 DOI:10.1067/mge.2002.125367]
57 Braden B,Halliday J,Aryasingha S,Sharifi Y,Checchin D,Warren BF,Kitiyakara T,Travis SP,Chapman RW.Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2012;10:303-308[PMID:22037429 DOI:10.1016/j.cgh.2011.10.020]
58 Lindstr?m L,Lapidus A,Ost A,Bergquist A.Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis.Dis Colon Rectum 2011;54:1392-1397[PMID:21979184 DOI:10.1097/DCR.0b013e31822bbcc1]
59 Ricciuto A,Kamath BM,Griffiths AM.The IBD and PSC Phenotypes of PSC-IBD.Curr Gastroenterol Rep 2018;20:16[PMID:29594739 DOI:10.1007/s11894-018-0620-2]
60 BrooméU,Bergquist A.Primary sclerosing cholangitis,inflammatory bowel disease,and colon cancer.Semin Liver Dis 2006;26:31-41[PMID:16496231 DOI:10.1055/s-2006-933561]
61 Shah SC,Ten Hove JR,Castaneda D,Palmela C,Mooiweer E,Colombel JF,Harpaz N,Ullman TA,van Bodegraven AA,Jansen JM,Mahmmod N,van der Meulen-de Jong AE,Ponsioen CY,van der Woude CJ,Oldenburg B,Itzkowitz SH,Torres J.High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.Clin Gastroenterol Hepatol2018;16:1106-1113.e3[PMID:29378311 DOI:10.1016/j.cgh.2018.01.023]
62 Brackmann S,Andersen SN,Aamodt G,Langmark F,Clausen OP,Aadland E,Fausa O,Rydning A,Vatn MH.Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.Scand J Gastroenterol 2009;44:46-55[PMID:18609187 DOI:10.1080/00365520801977568]
63 Claessen MM,Lutgens MW,van Buuren HR,Oldenburg B,Stokkers PC,van der Woude CJ,Hommes DW,de Jong DJ,Dijkstra G,van Bodegraven AA,Siersema PD,Vleggaar FP.More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis.Inflamm Bowel Dis 2009;15:1331-1336[PMID:19229982 DOI:10.1002/ibd.20886]
64 Navaneethan U,Kochhar G,Venkatesh PG,Lewis B,Lashner BA,Remzi FH,Shen B,Kiran RP.Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.Gastrointest Endosc 2012;75:1045-1054.e1[PMID:22405258 DOI:10.1016/j.gie.2012.01.015]
65 Thackeray EW,Charatcharoenwitthaya P,Elfaki D,Sinakos E,Lindor KD.Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2011;9:52-56[PMID:20920596 DOI:10.1016/j.cgh.2010.09.020]
66 Rao BB,Lashner B,Kowdley KV.Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.Inflamm Bowel Dis 2018;24:269-276[PMID:29361103 DOI:10.1093/ibd/izx056]
67 Fevery J,Henckaerts L,Van Oirbeek R,Vermeire S,Rutgeerts P,Nevens F,Van Steenbergen W.Malignancies and mortality in 200 patients with primary sclerosering cholangitis:A long-term singlecentre study.Liver Int 2012;32:214-222[PMID:21745316 DOI:10.1111/j.1478-3231.2011.02575.x]
68 Pardi DS,Loftus EV,Kremers WK,Keach J,Lindor KD.Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.Gastroenterology 2003;124:889-893[PMID:12671884 DOI:10.1053/gast.2003.50156]
69 Tung BY,Emond MJ,Haggitt RC,Bronner MP,Kimmey MB,Kowdley KV,Brentnall TA.Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Ann Intern Med 2001;134:89-95[PMID:11177311 DOI:10.7326/0003-4819-134-2-200101160-00008]
70 Lindstr?m L,Boberg KM,Wikman O,Friis-Liby I,Hultcrantz R,Prytz H,Sandberg-Gertzén H,Sangfelt P,Rydning A,Folvik G,Gangs?y-Kristiansen M,Danielsson A,Bergquist A.High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.Aliment Pharmacol Ther2012;35:451-457[PMID:22221173 DOI:10.1111/j.1365-2036.2011.04966.x]
71 Eaton JE,Silveira MG,Pardi DS,Sinakos E,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Lindor KD.High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Am J Gastroenterol 2011;106:1638-1645[PMID:21556038 DOI:10.1038/ajg.2011.156]
72 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
73 de Chambrun GP,Nachury M,Funakoshi N,Gerard R,Bismuth M,Valats JC,Panaro F,Navarro F,Desreumaux P,Pariente B,Blanc P.Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.Eur J Gastroenterol Hepatol 2018;30:1247-1252[PMID:30052539 DOI:10.1097/MEG.0000000000001223]
74 Tan LZ,Reilly CR,Steward-Harrison LC,Balouch F,Muir R,Lewindon PJ.Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.Gut 2018;pii:gutjnl-2018-316599[PMID:30131321 DOI:10.1136/gutjnl-2018-316599]
75 Davies YK,Tsay CJ,Caccamo DV,Cox KM,Castillo RO,Cox KL.Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin.Case Rep Transplant 2013;2013:314292[PMID:23509657 DOI:10.1155/2013/314292]
76 Lindor K.Vancomycin for Primary Sclerosing Cholangitis.[accessed 2018-10-22]In:ClinicalTrials.gov[Internet].Bethesda(MD):U.S.National Library of Medicine.ClinicalTrials.gov Identifier:NCT03710122.Available from:https://clinicaltrials.gov/ct2/show/NCT03710122
77 Hu RW,Carey EJ,Lindor KD,Tabibian JH.Curcumin in Hepatobiliary Disease:Pharmacotherapeutic Properties and Emerging Potential Clinical Applications.Ann Hepatol 2017;16:835-841[PMID:29055920 DOI:10.5604/01.3001.0010.5273]
78 Eaton JE.A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis.[accessed 2018-10-20]In:ClinicalTrials.gov[Internet].Bethesda(MD):U.S.National Library of Medicine.ClinicalTrials.gov Identifier:NCT02978339.Available from:https://clinicaltrials.gov/ct2/show/NCT02978339
79 Chalasani N,Baluyut A,Ismail A,Zaman A,Sood G,Ghalib R,McCashland TM,Reddy KR,Zervos X,Anbari MA,Hoen H.Cholangiocarcinoma in patients with primary sclerosing cholangitis:A multicenter case-control study.Hepatology 2000;31:7-11[PMID:10613720 DOI:10.1002/hep.510310103]
80 Schramm C,Eaton J,Ringe KI,Venkatesh S,Yamamura J,MRI working group of the IPSCSG.Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.Hepatology 2017;66:1675-1688[PMID:28555945 DOI:10.1002/hep.29293]
81 Charatcharoenwitthaya P,Enders FB,Halling KC,Lindor KD.Utility of serum tumor markers,imaging,and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.Hepatology 2008;48:1106-1117[PMID:18785620 DOI:10.1002/hep.22441]
82 Wannhoff A,Gotthardt DN.Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis.Clin Res Hepatol Gastroenterol 2018;pii:S2210-7401(18)30177-3[PMID:30266579 DOI:10.1016/j.clinre.2018.08.013]
83 Cuenco J,Wehnert N,Blyuss O,Kazarian A,Whitwell HJ,Menon U,Dawnay A,Manns MP,Pereira SP,Timms JF.Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.Oncotarget 2018;9:17430-17442[PMID:29707118 DOI:10.18632/oncotarget.24732]
84 Navaneethan U,Parsi MA,Lourdusamy V,Bhatt A,Gutierrez NG,Grove D,Sanaka MR,Hammel JP,Stevens T,Vargo JJ,Dweik RA.Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis:A pilot study.Gastrointest Endosc2015;81:943-9.e1[PMID:25500329 DOI:10.1016/j.gie.2014.09.041]
85 Trikudanathan G,Navaneethan U,Njei B,Vargo JJ,Parsi MA.Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis:A systematic review and meta-analysis.Gastrointest Endosc 2014;79:783-789[PMID:24140129 DOI:10.1016/j.gie.2013.09.015]
86 Kipp BR,Stadheim LM,Halling SA,Pochron NL,Harmsen S,Nagorney DM,Sebo TJ,Therneau TM,Gores GJ,de Groen PC,Baron TH,Levy MJ,Halling KC,Roberts LR.A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.Am JGastroenterol 2004;99:1675-1681[PMID:15330900 DOI:10.1111/j.1572-0241.2004.30281.x]
87 Bangarulingam SY,Bjornsson E,Enders F,Barr Fritcher EG,Gores G,Halling KC,Lindor KD.Longterm outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.Hepatology 2010;51:174-180[PMID:19877179 DOI:10.1002/hep.23277]
88 Bangarulingam SY,Gossard AA,Petersen BT,Ott BJ,Lindor KD.Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis.Am J Gastroenterol 2009;104:855-860[PMID:19259076 DOI:10.1038/ajg.2008.161]
89 Zamora-Valdes D,Heimbach JK.Liver Transplant for Cholangiocarcinoma.Gastroenterol Clin North Am 2018;47:267-280[PMID:29735023 DOI:10.1016/j.gtc.2018.01.002]
90 Stremitzer S,Jones RP,Quinn LM,Fenwick SW,Diaz-Nieto R,Poston GJ,Malik HZ.Clinical outcome after resection of early-stage hilar cholangiocarcinoma.Eur J Surg Oncol 2018;pii:S0748-7983(18)31427-6[PMID:30360988 DOI:10.1016/j.ejso.2018.09.008]
91 De Vreede I,Steers JL,Burch PA,Rosen CB,Gunderson LL,Haddock MG,Burgart L,Gores GJ.Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.Liver Transpl 2000;6:309-316[PMID:10827231 DOI:10.1053/lv.2000.6143]
92 Darwish Murad S,Kim WR,Harnois DM,Douglas DD,Burton J,Kulik LM,Botha JF,Mezrich JD,Chapman WC,Schwartz JJ,Hong JC,Emond JC,Jeon H,Rosen CB,Gores GJ,Heimbach JK.Efficacy of neoadjuvant chemoradiation,followed by liver transplantation,for perihilar cholangiocarcinoma at 12 UScenters.Gastroenterology 2012;143:88-98.e3;quiz e14[PMID:22504095 DOI:10.1053/j.gastro.2012.04.008]
93 Vijayakumar A,Vijayakumar A,Patil V,Mallikarjuna MN,Shivaswamy BS.Early diagnosis of gallbladder carcinoma:An algorithm approach.ISRN Radiol 2012;2013:239424[PMID:24959553 DOI:10.5402/2013/239424]
94 Shirai Y,Yoshida K,Tsukada K,Muto T.Inapparent carcinoma of the gallbladder.An appraisal of a radical second operation after simple cholecystectomy.Ann Surg 1992;215:326-331[PMID:1558412]
95 Bruix J,Sherman M;Practice Guidelines Committee,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236[PMID:16250051DOI:10.1002/hep.20933]
96 Zenouzi R,Weismüller TJ,Hübener P,Schulze K,Bubenheim M,Pannicke N,Weiler-Normann C,Lenzen H,Manns MP,Lohse AW,Schramm C.Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.Clin Gastroenterol Hepatol 2014;12:1733-1738[PMID:24530461 DOI:10.1016/j.cgh.2014.02.008]
97 Gossard AA,Lindor KD.Hepatocellular carcinoma:Low risk of HCC in patients who have PSC and cirrhosis.Nat Rev Gastroenterol Hepatol 2014;11:276-277[PMID:24686269 DOI:10.1038/nrgastro.2014.47]
98 Khaderi SA,Sussman NL.Screening for malignancy in primary sclerosing cholangitis(PSC).Curr Gastroenterol Rep 2015;17:17[PMID:25786901 DOI:10.1007/s11894-015-0438-0]
99 Ayuso C,Rimola J,Vilana R,Burrel M,Darnell A,García-Criadoá,Bianchi L,Belmonte E,Caparroz C,Barrufet M,Bruix J,BrúC.Diagnosis and staging of hepatocellular carcinoma(HCC):Current guidelines.Eur J Radiol 2018;101:72-81[PMID:29571804 DOI:10.1016/j.ejrad.2018.01.025]
100 Moussata D,Allez M,Cazals-Hatem D,Treton X,Laharie D,Reimund JM,Bertheau P,Bourreille A,Lavergne-Slove A,Brixi H,Branche J,Gornet JM,Stefanescu C,Moreau J,Marteau P,Pelletier AL,Carbonnel F,Seksik P,Simon M,Flé,jou JF,Colombel JF,Charlois AL,Roblin X,Nancey S,Bouhnik Y,Berger F,Flourié,B,the GETAID.Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?Gut 2018;67:616-624[PMID:28115492 DOI:10.1136/gutjnl-2016-311892]
101 van den Broek FJ,Stokkers PC,Reitsma JB,Boltjes RP,Ponsioen CY,Fockens P,Dekker E.Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis:Low yield and absence of clinical consequences.Am J Gastroenterol 2014;109:715-722[PMID:21427710 DOI:10.1038/ajg.2011.93]
102 Navaneethan U,Kochhar G,Venkatesh PG,Bennett AE,Rizk M,Shen B,Kiran RP.Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis.J Crohns Colitis 2013;7:974-981[PMID:23523416 DOI:10.1016/j.crohns.2013.02.009]
103 Tabibian JH,Ali AH,Lindor KD.Primary Sclerosing Cholangitis,Part 2:Cancer Risk,Prevention,and Surveillance.Gastroenterol Hepatol(NY)2018;14:427-432[PMID:30166959 DOI:10.6000/1927-7229.2012.01.01.7]
2 Tabibian JH,Lindor KD.Primary sclerosing cholangitis:A review and update on therapeutic developments.Expert Rev Gastroenterol Hepatol 2013;7:103-114[PMID:23363260 DOI:10.1586/egh.12.80]
3 O’Hara SP,Tabibian JH,Splinter PL,LaRusso NF.The dynamic biliary epithelia:Molecules,pathways,and disease.J Hepatol 2013;58:575-582[PMID:23085249 DOI:10.1016/j.jhep.2012.10.011]
4 Porayko MK,Wiesner RH,LaRusso NF,Ludwig J,MacCarty RL,Steiner BL,Twomey CK,Zinsmeister AR.Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease.Gastroenterology 1990;98:1594-1602[PMID:2338198 DOI:10.1016/0016-5085(90)91096-O]
5 Boonstra K,Weersma RK,van Erpecum KJ,Rauws EA,Spanier BW,Poen AC,van Nieuwkerk KM,Drenth JP,Witteman BJ,Tuynman HA,Naber AH,Kingma PJ,van Buuren HR,van Hoek B,Vleggaar FP,van Geloven N,Beuers U,Ponsioen CY;EpiPSCPBC Study Group.Population-based epidemiology,malignancy risk,and outcome of primary sclerosing cholangitis.Hepatology 2013;58:2045-2055[PMID:23775876 DOI:10.1002/hep.26565]
6 Takakura WR,Tabibian JH,Bowlus CL.The evolution of natural history of primary sclerosing cholangitis.Curr Opin Gastroenterol 2017;33:71-77[PMID:28030370 DOI:10.1097/MOG.0000000000000333]
7 Boonstra K,Beuers U,Ponsioen CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:A systematic review.J Hepatol 2012;56:1181-1188[PMID:22245904 DOI:10.1016/j.jhep.2011.10.025]
8 Molodecky NA,Kareemi H,Parab R,Barkema HW,Quan H,Myers RP,Kaplan GG.Incidence of primary sclerosing cholangitis:A systematic review and meta-analysis.Hepatology 2011;53:1590-1599[PMID:21351115 DOI:10.1002/hep.24247]
9 Tsaitas C,Semertzidou A,Sinakos E.Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.World J Hepatol 2014;6:178-187[PMID:24799986 DOI:10.4254/wjh.v6.i4.178]
10 Silveira MG,Mendes FD,Diehl NN,Enders FT,Lindor KD.Thyroid dysfunction in primary biliary cirrhosis,primary sclerosing cholangitis and non-alcoholic fatty liver disease.Liver Int 2009;29:1094-1100[PMID:19291181 DOI:10.1111/j.1478-3231.2009.02003.x]
11 Lamberts LE,Janse M,Haagsma EB,van den Berg AP,Weersma RK.Immune-mediated diseases in primary sclerosing cholangitis.Dig Liver Dis 2011;43:802-806[PMID:21700515 DOI:10.1016/j.dld.2011.05.009]
12 Rupp C,Mummelthei A,Sauer P,Weiss KH,Schirmacher P,Stiehl A,Stremmel W,Gotthardt DN.NonIBD immunological diseases are a risk factor for reduced survival in PSC.Liver Int 2013;33:86-93[PMID:23157607 DOI:10.1111/liv.12028]
13 Folseraas T,Boberg KM.Cancer Risk and Surveillance in Primary Sclerosing Cholangitis.Clin Liver Dis2016;20:79-98[PMID:26593292 DOI:10.1016/j.cld.2015.08.014]
14 Gulamhusein AF,Eaton JE,Tabibian JH,Atkinson EJ,Juran BD,Lazaridis KN.Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.Am J Gastroenterol 2016;111:705-711[PMID:27002801 DOI:10.1038/ajg.2016.55]
15 Bergquist A,Ekbom A,Olsson R,Kornfeldt D,L??f L,Danielsson A,Hultcrantz R,Lindgren S,Prytz H,Sandberg-Gertzén H,Almer S,Granath F,BrooméU.Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.J Hepatol 2002;36:321-327[PMID:11867174 DOI:10.1016/S0168-8278(01)00288-4]
16 Claessen MM,Vleggaar FP,Tytgat KM,Siersema PD,van Buuren HR.High lifetime risk of cancer in primary sclerosing cholangitis.J Hepatol 2009;50:158-164[PMID:19012991 DOI:10.1016/j.jhep.2008.08.013]
17 Card TR,Solaymani-Dodaran M,West J.Incidence and mortality of primary sclerosing cholangitis in the UK:A population-based cohort study.J Hepatol 2008;48:939-944[PMID:18433916 DOI:10.1016/j.jhep.2008.02.017]
18 Zheng HH,Jiang XL.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease:A meta-analysis of 16 observational studies.Eur J Gastroenterol Hepatol 2016;28:383-390[PMID:26938805 DOI:10.1097/MEG.0000000000000576]
19 Said K,Glaumann H,Bergquist A.Gallbladder disease in patients with primary sclerosing cholangitis.JHepatol 2008;48:598-605[PMID:18222013 DOI:10.1016/j.jhep.2007.11.019]
20 Fevery J,Verslype C,Lai G,Aerts R,Van Steenbergen W.Incidence,diagnosis,and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.Dig Dis Sci 2007;52:3123-3135[PMID:17431781 DOI:10.1007/s10620-006-9681-4]
21 Weismüller TJ,Trivedi PJ,Bergquist A,Imam M,Lenzen H,Ponsioen CY,Holm K,Gotthardt D,F?rkkil?MA,Marschall HU,Thorburn D,Weersma RK,Fevery J,Mueller T,Chazouillères O,Schulze K,Lazaridis KN,Almer S,Pereira SP,Levy C,Mason A,Naess S,Bowlus CL,Floreani A,Halilbasic E,Yimam KK,Milkiewicz P,Beuers U,Huynh DK,Pares A,Manser CN,Dalekos GN,Eksteen B,Invernizzi P,Berg CP,Kirchner GI,Sarrazin C,Zimmer V,Fabris L,Braun F,Marzioni M,Juran BD,Said K,Rupp C,Jokelainen K,Benito de Valle M,Saffioti F,Cheung A,Trauner M,Schramm C,Chapman RW,Karlsen TH,Schrumpf E,Strassburg CP,Manns MP,Lindor KD,Hirschfield GM,Hansen BE,Boberg KM;International PSC Study Group.Patient Age,Sex,and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.Gastroenterology 2017;152:1975-1984.e8[PMID:28274849 DOI:10.1053/j.gastro.2017.02.038]
22 Burak K,Angulo P,Pasha TM,Egan K,Petz J,Lindor KD.Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.Am J Gastroenterol 2004;99:523-526[PMID:15056096 DOI:10.1111/j.1572-0241.2004.04067.x]
23 Ahrendt SA,Pitt HA,Nakeeb A,Klein AS,Lillemoe KD,Kalloo AN,Cameron JL.Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.J Gastrointest Surg 1999;3:357-67;discussion 367-8[PMID:10482687 DOI:10.1016/S1091-255X(99)80051-1]
24 Blechacz B.Cholangiocarcinoma:Current Knowledge and New Developments.Gut Liver 2017;11:13-26[PMID:27928095 DOI:10.5009/gnl15568]
25 Bergquist A,Glaumann H,Persson B,BrooméU.Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis:A case-control study.Hepatology 1998;27:311-316[PMID:9462625 DOI:10.1002/hep.510270201]
26 Ghouri YA,Mian I,Blechacz B.Cancer review:Cholangiocarcinoma.J Carcinog 2015;14:1[PMID:25788866 DOI:10.4103/1477-3163.151940]
27 Chapman MH,Webster GJ,Bannoo S,Johnson GJ,Wittmann J,Pereira SP.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis:A 25-year single-centre experience.Eur J Gastroenterol Hepatol 2012;24:1051-1058[PMID:22653260 DOI:10.1097/MEG.0b013e3283554bbf]
28 DeOliveira ML,Cunningham SC,Cameron JL,Kamangar F,Winter JM,Lillemoe KD,Choti MA,Yeo CJ,Schulick RD.Cholangiocarcinoma:Thirty-one-year experience with 564 patients at a single institution.Ann Surg 2007;245:755-762[PMID:17457168 DOI:10.1097/01.sla.0000251366.62632.d3]
29 Lee WJ,Lim HK,Jang KM,Kim SH,Lee SJ,Lim JH,Choo IW.Radiologic spectrum of cholangiocarcinoma:emphasis on unusual manifestations and differential diagnoses.Radiographics 2001;21 Spec No:S97-S116[PMID:11598251 DOI:10.1148/radiographics.21.suppl_1.g01oc12s97]
30 Fevery J,Verslype C.An update on cholangiocarcinoma associated with primary sclerosing cholangitis.Curr Opin Gastroenterol 2010;26:236-245[PMID:20216413 DOI:10.1097/MOG.0b013e328337b311]
31 Karlsen TH,Folseraas T,Thorburn D,Vesterhus M.Primary sclerosing cholangitis-a comprehensive review.J Hepatol 2017;67:1298-1323[PMID:28802875 DOI:10.1016/j.jhep.2017.07.022]
32 Hilscher MB,Tabibian JH,Carey EJ,Gostout CJ,Lindor KD.Dominant strictures in primary sclerosing cholangitis:A multicenter survey of clinical definitions and practices.Hepatol Commun 2018;2:836-844[PMID:30027141 DOI:10.1002/hep4.1194]
33 Lazaridis KN,Gores GJ.Primary sclerosing cholangitis and cholangiocarcinoma.Semin Liver Dis 2006;26:42-51[PMID:16496232 DOI:10.1055/s-2006-933562]
34 Mouchli MA,Singh S,Loftus EV,Boardman L,Talwalkar J,Rosen CB,Heimbach JK,Wiesner RH,Hasan B,Poterucha JJ,Kymberly WD.Risk Factors and Outcomes of De Novo Cancers(Excluding Nonmelanoma Skin Cancer)After Liver Transplantation for Primary Sclerosing Cholangitis.Transplantation 2017;101:1859-1866[PMID:28272287 DOI:10.1097/TP.0000000000001725]
35 Khorsandi SE,Salvans S,Zen Y,Agarwal K,Jassem W,Heaton N.Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation.Transpl Int 2011;24:e93-e96[PMID:21884553 DOI:10.1111/j.1432-2277.2011.01324.x]
36 Watt KD,Pedersen RA,Kremers WK,Heimbach JK,Sanchez W,Gores GJ.Long-term probability of and mortality from de novo malignancy after liver transplantation.Gastroenterology 2009;137:2010-2017[PMID:19766646 DOI:10.1053/j.gastro.2009.08.070]
37 Landaverde C,Ng V,Sato A,Tabibian J,Durazo F,Busuttil R.De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis.Ann Hepatol 2009;8:379-383[PMID:20009140 DOI:10.1152/ajpgi.90631.2008]
38 Heneghan MA,Tuttle-Newhall JE,Suhocki PV,Muir AJ,Morse M,Bornstein JD,Sylvestre PB,Collins B,Kuo PC,Rockey DC.De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant.Am J Transplant 2003;3:634-638[PMID:12752322 DOI:10.1034/j.1600-6143.2003.00110.x]
39 Tabibian JH,Bowlus CL.Primary sclerosing cholangitis:A review and update.Liver Res 2017;1:221-230[PMID:29977644 DOI:10.1016/j.livres.2017.12.002]
40 Tabibian J,Lazaridis K,LaRusso N,Jarnagin W.Primary Sclerosing Cholangitis.Jarnagin W.Blumgart’s Surgery of the Liver,Biliary Tract and Pancreas.Philadelphia,PA,United States:Elsevier;2017;663-674
41 Karlsen TH,Schrumpf E,Boberg KM.Gallbladder polyps in primary sclerosing cholangitis:Not so benign.Curr Opin Gastroenterol 2008;24:395-399[PMID:18408471 DOI:10.1097/MOG.0b013e3282f5727a]
42 Buckles DC,Lindor KD,Larusso NF,Petrovic LM,Gores GJ.In primary sclerosing cholangitis,gallbladder polyps are frequently malignant.Am J Gastroenterol 2002;97:1138-1142[PMID:12014717DOI:10.1111/j.1572-0241.2002.05677.x]
43 Sandrasegaran K,Menias CO.Imaging and Screening of Cancer of the Gallbladder and Bile Ducts.Radiol Clin North Am 2017;55:1211-1222[PMID:28991561 DOI:10.1016/j.rcl.2017.06.005]
44 Chapman R,Fevery J,Kalloo A,Nagorney DM,Boberg KM,Shneider B,Gores GJ;American Association for the Study of Liver Diseases.Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010;51:660-678[PMID:20101749 DOI:10.1002/hep.23294]
45 European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of cholestatic liver diseases.J Hepatol 2009;51:237-267[PMID:19501929 DOI:10.1016/j.jhep.2009.04.009]
46 Lindor KD,Kowdley KV,Harrison ME;American College of Gastroenterology.ACG Clinical Guideline:Primary Sclerosing Cholangitis.Am J Gastroenterol 2015;110:646-59;quiz 660[PMID:25869391 DOI:10.1038/ajg.2015.112]
47 Eaton JE,Thackeray EW,Lindor KD.Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis.Am J Gastroenterol 2012;107:431-439[PMID:22031356 DOI:10.1038/ajg.2011.361]
48 Razumilava N,Gores GJ,Lindor KD.Cancer surveillance in patients with primary sclerosing cholangitis.Hepatology 2011;54:1842-1852[PMID:21793028 DOI:10.1002/hep.24570]
49 Harnois DM,Gores GJ,Ludwig J,Steers JL,LaRusso NF,Wiesner RH.Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?J Hepatol 1997;27:512-516[PMID:9314129 DOI:10.1016/S0168-8278(97)80356-X]
50 Leidenius M,H?ckersted K,BrooméU,Ericzon BG,Friman S,Olausson M,Schrumpf E.Hepatobiliary carcinoma in primary sclerosing cholangitis:A case control study.J Hepatol 2001;34:792-798[PMID:11451160 DOI:10.1016/S0168-8278(01)00042-3]
51 Ali AH,Tabibian JH,Nasser-Ghodsi N,Lennon RJ,DeLeon T,Borad MJ,Hilscher M,Silveira MG,Carey EJ,Lindor KD.Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.Hepatology 2018;67:2338-2351[PMID:29244227 DOI:10.1002/hep.29730]
52 Francescone R,Hou V,Grivennikov SI.Cytokines,IBD,and colitis-associated cancer.Inflamm Bowel Dis 2015;21:409-418[PMID:25563695 DOI:10.1097/MIB.0000000000000236]
53 de Vries AB,Janse M,Blokzijl H,Weersma RK.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol 2015;21:1956-1971[PMID:25684965 DOI:10.3748/wjg.v21.i6.1956]
54 Loftus EV,Harewood GC,Loftus CG,Tremaine WJ,Harmsen WS,Zinsmeister AR,Jewell DA,Sandborn WJ.PSC-IBD:A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.Gut 2005;54:91-96[PMID:15591511 DOI:10.1136/gut.2004.046615]
55 BrooméU,L?fberg R,Veress B,Eriksson LS.Primary sclerosing cholangitis and ulcerative colitis:Evidence for increased neoplastic potential.Hepatology 1995;22:1404-1408[PMID:7590655 DOI:10.1002/hep.1840220511]
56 Soetikno RM,Lin OS,Heidenreich PA,Young HS,Blackstone MO.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis:A meta-analysis.Gastrointest Endosc2002;56:48-54[PMID:12085034 DOI:10.1067/mge.2002.125367]
57 Braden B,Halliday J,Aryasingha S,Sharifi Y,Checchin D,Warren BF,Kitiyakara T,Travis SP,Chapman RW.Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2012;10:303-308[PMID:22037429 DOI:10.1016/j.cgh.2011.10.020]
58 Lindstr?m L,Lapidus A,Ost A,Bergquist A.Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis.Dis Colon Rectum 2011;54:1392-1397[PMID:21979184 DOI:10.1097/DCR.0b013e31822bbcc1]
59 Ricciuto A,Kamath BM,Griffiths AM.The IBD and PSC Phenotypes of PSC-IBD.Curr Gastroenterol Rep 2018;20:16[PMID:29594739 DOI:10.1007/s11894-018-0620-2]
60 BrooméU,Bergquist A.Primary sclerosing cholangitis,inflammatory bowel disease,and colon cancer.Semin Liver Dis 2006;26:31-41[PMID:16496231 DOI:10.1055/s-2006-933561]
61 Shah SC,Ten Hove JR,Castaneda D,Palmela C,Mooiweer E,Colombel JF,Harpaz N,Ullman TA,van Bodegraven AA,Jansen JM,Mahmmod N,van der Meulen-de Jong AE,Ponsioen CY,van der Woude CJ,Oldenburg B,Itzkowitz SH,Torres J.High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.Clin Gastroenterol Hepatol2018;16:1106-1113.e3[PMID:29378311 DOI:10.1016/j.cgh.2018.01.023]
62 Brackmann S,Andersen SN,Aamodt G,Langmark F,Clausen OP,Aadland E,Fausa O,Rydning A,Vatn MH.Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.Scand J Gastroenterol 2009;44:46-55[PMID:18609187 DOI:10.1080/00365520801977568]
63 Claessen MM,Lutgens MW,van Buuren HR,Oldenburg B,Stokkers PC,van der Woude CJ,Hommes DW,de Jong DJ,Dijkstra G,van Bodegraven AA,Siersema PD,Vleggaar FP.More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis.Inflamm Bowel Dis 2009;15:1331-1336[PMID:19229982 DOI:10.1002/ibd.20886]
64 Navaneethan U,Kochhar G,Venkatesh PG,Lewis B,Lashner BA,Remzi FH,Shen B,Kiran RP.Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.Gastrointest Endosc 2012;75:1045-1054.e1[PMID:22405258 DOI:10.1016/j.gie.2012.01.015]
65 Thackeray EW,Charatcharoenwitthaya P,Elfaki D,Sinakos E,Lindor KD.Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis.Clin Gastroenterol Hepatol 2011;9:52-56[PMID:20920596 DOI:10.1016/j.cgh.2010.09.020]
66 Rao BB,Lashner B,Kowdley KV.Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.Inflamm Bowel Dis 2018;24:269-276[PMID:29361103 DOI:10.1093/ibd/izx056]
67 Fevery J,Henckaerts L,Van Oirbeek R,Vermeire S,Rutgeerts P,Nevens F,Van Steenbergen W.Malignancies and mortality in 200 patients with primary sclerosering cholangitis:A long-term singlecentre study.Liver Int 2012;32:214-222[PMID:21745316 DOI:10.1111/j.1478-3231.2011.02575.x]
68 Pardi DS,Loftus EV,Kremers WK,Keach J,Lindor KD.Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.Gastroenterology 2003;124:889-893[PMID:12671884 DOI:10.1053/gast.2003.50156]
69 Tung BY,Emond MJ,Haggitt RC,Bronner MP,Kimmey MB,Kowdley KV,Brentnall TA.Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Ann Intern Med 2001;134:89-95[PMID:11177311 DOI:10.7326/0003-4819-134-2-200101160-00008]
70 Lindstr?m L,Boberg KM,Wikman O,Friis-Liby I,Hultcrantz R,Prytz H,Sandberg-Gertzén H,Sangfelt P,Rydning A,Folvik G,Gangs?y-Kristiansen M,Danielsson A,Bergquist A.High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.Aliment Pharmacol Ther2012;35:451-457[PMID:22221173 DOI:10.1111/j.1365-2036.2011.04966.x]
71 Eaton JE,Silveira MG,Pardi DS,Sinakos E,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Lindor KD.High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Am J Gastroenterol 2011;106:1638-1645[PMID:21556038 DOI:10.1038/ajg.2011.156]
72 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
73 de Chambrun GP,Nachury M,Funakoshi N,Gerard R,Bismuth M,Valats JC,Panaro F,Navarro F,Desreumaux P,Pariente B,Blanc P.Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.Eur J Gastroenterol Hepatol 2018;30:1247-1252[PMID:30052539 DOI:10.1097/MEG.0000000000001223]
74 Tan LZ,Reilly CR,Steward-Harrison LC,Balouch F,Muir R,Lewindon PJ.Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.Gut 2018;pii:gutjnl-2018-316599[PMID:30131321 DOI:10.1136/gutjnl-2018-316599]
75 Davies YK,Tsay CJ,Caccamo DV,Cox KM,Castillo RO,Cox KL.Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin.Case Rep Transplant 2013;2013:314292[PMID:23509657 DOI:10.1155/2013/314292]
76 Lindor K.Vancomycin for Primary Sclerosing Cholangitis.[accessed 2018-10-22]In:ClinicalTrials.gov[Internet].Bethesda(MD):U.S.National Library of Medicine.ClinicalTrials.gov Identifier:NCT03710122.Available from:https://clinicaltrials.gov/ct2/show/NCT03710122
77 Hu RW,Carey EJ,Lindor KD,Tabibian JH.Curcumin in Hepatobiliary Disease:Pharmacotherapeutic Properties and Emerging Potential Clinical Applications.Ann Hepatol 2017;16:835-841[PMID:29055920 DOI:10.5604/01.3001.0010.5273]
78 Eaton JE.A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis.[accessed 2018-10-20]In:ClinicalTrials.gov[Internet].Bethesda(MD):U.S.National Library of Medicine.ClinicalTrials.gov Identifier:NCT02978339.Available from:https://clinicaltrials.gov/ct2/show/NCT02978339
79 Chalasani N,Baluyut A,Ismail A,Zaman A,Sood G,Ghalib R,McCashland TM,Reddy KR,Zervos X,Anbari MA,Hoen H.Cholangiocarcinoma in patients with primary sclerosing cholangitis:A multicenter case-control study.Hepatology 2000;31:7-11[PMID:10613720 DOI:10.1002/hep.510310103]
80 Schramm C,Eaton J,Ringe KI,Venkatesh S,Yamamura J,MRI working group of the IPSCSG.Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.Hepatology 2017;66:1675-1688[PMID:28555945 DOI:10.1002/hep.29293]
81 Charatcharoenwitthaya P,Enders FB,Halling KC,Lindor KD.Utility of serum tumor markers,imaging,and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.Hepatology 2008;48:1106-1117[PMID:18785620 DOI:10.1002/hep.22441]
82 Wannhoff A,Gotthardt DN.Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis.Clin Res Hepatol Gastroenterol 2018;pii:S2210-7401(18)30177-3[PMID:30266579 DOI:10.1016/j.clinre.2018.08.013]
83 Cuenco J,Wehnert N,Blyuss O,Kazarian A,Whitwell HJ,Menon U,Dawnay A,Manns MP,Pereira SP,Timms JF.Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.Oncotarget 2018;9:17430-17442[PMID:29707118 DOI:10.18632/oncotarget.24732]
84 Navaneethan U,Parsi MA,Lourdusamy V,Bhatt A,Gutierrez NG,Grove D,Sanaka MR,Hammel JP,Stevens T,Vargo JJ,Dweik RA.Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis:A pilot study.Gastrointest Endosc2015;81:943-9.e1[PMID:25500329 DOI:10.1016/j.gie.2014.09.041]
85 Trikudanathan G,Navaneethan U,Njei B,Vargo JJ,Parsi MA.Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis:A systematic review and meta-analysis.Gastrointest Endosc 2014;79:783-789[PMID:24140129 DOI:10.1016/j.gie.2013.09.015]
86 Kipp BR,Stadheim LM,Halling SA,Pochron NL,Harmsen S,Nagorney DM,Sebo TJ,Therneau TM,Gores GJ,de Groen PC,Baron TH,Levy MJ,Halling KC,Roberts LR.A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.Am JGastroenterol 2004;99:1675-1681[PMID:15330900 DOI:10.1111/j.1572-0241.2004.30281.x]
87 Bangarulingam SY,Bjornsson E,Enders F,Barr Fritcher EG,Gores G,Halling KC,Lindor KD.Longterm outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.Hepatology 2010;51:174-180[PMID:19877179 DOI:10.1002/hep.23277]
88 Bangarulingam SY,Gossard AA,Petersen BT,Ott BJ,Lindor KD.Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis.Am J Gastroenterol 2009;104:855-860[PMID:19259076 DOI:10.1038/ajg.2008.161]
89 Zamora-Valdes D,Heimbach JK.Liver Transplant for Cholangiocarcinoma.Gastroenterol Clin North Am 2018;47:267-280[PMID:29735023 DOI:10.1016/j.gtc.2018.01.002]
90 Stremitzer S,Jones RP,Quinn LM,Fenwick SW,Diaz-Nieto R,Poston GJ,Malik HZ.Clinical outcome after resection of early-stage hilar cholangiocarcinoma.Eur J Surg Oncol 2018;pii:S0748-7983(18)31427-6[PMID:30360988 DOI:10.1016/j.ejso.2018.09.008]
91 De Vreede I,Steers JL,Burch PA,Rosen CB,Gunderson LL,Haddock MG,Burgart L,Gores GJ.Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.Liver Transpl 2000;6:309-316[PMID:10827231 DOI:10.1053/lv.2000.6143]
92 Darwish Murad S,Kim WR,Harnois DM,Douglas DD,Burton J,Kulik LM,Botha JF,Mezrich JD,Chapman WC,Schwartz JJ,Hong JC,Emond JC,Jeon H,Rosen CB,Gores GJ,Heimbach JK.Efficacy of neoadjuvant chemoradiation,followed by liver transplantation,for perihilar cholangiocarcinoma at 12 UScenters.Gastroenterology 2012;143:88-98.e3;quiz e14[PMID:22504095 DOI:10.1053/j.gastro.2012.04.008]
93 Vijayakumar A,Vijayakumar A,Patil V,Mallikarjuna MN,Shivaswamy BS.Early diagnosis of gallbladder carcinoma:An algorithm approach.ISRN Radiol 2012;2013:239424[PMID:24959553 DOI:10.5402/2013/239424]
94 Shirai Y,Yoshida K,Tsukada K,Muto T.Inapparent carcinoma of the gallbladder.An appraisal of a radical second operation after simple cholecystectomy.Ann Surg 1992;215:326-331[PMID:1558412]
95 Bruix J,Sherman M;Practice Guidelines Committee,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236[PMID:16250051DOI:10.1002/hep.20933]
96 Zenouzi R,Weismüller TJ,Hübener P,Schulze K,Bubenheim M,Pannicke N,Weiler-Normann C,Lenzen H,Manns MP,Lohse AW,Schramm C.Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.Clin Gastroenterol Hepatol 2014;12:1733-1738[PMID:24530461 DOI:10.1016/j.cgh.2014.02.008]
97 Gossard AA,Lindor KD.Hepatocellular carcinoma:Low risk of HCC in patients who have PSC and cirrhosis.Nat Rev Gastroenterol Hepatol 2014;11:276-277[PMID:24686269 DOI:10.1038/nrgastro.2014.47]
98 Khaderi SA,Sussman NL.Screening for malignancy in primary sclerosing cholangitis(PSC).Curr Gastroenterol Rep 2015;17:17[PMID:25786901 DOI:10.1007/s11894-015-0438-0]
99 Ayuso C,Rimola J,Vilana R,Burrel M,Darnell A,García-Criadoá,Bianchi L,Belmonte E,Caparroz C,Barrufet M,Bruix J,BrúC.Diagnosis and staging of hepatocellular carcinoma(HCC):Current guidelines.Eur J Radiol 2018;101:72-81[PMID:29571804 DOI:10.1016/j.ejrad.2018.01.025]
100 Moussata D,Allez M,Cazals-Hatem D,Treton X,Laharie D,Reimund JM,Bertheau P,Bourreille A,Lavergne-Slove A,Brixi H,Branche J,Gornet JM,Stefanescu C,Moreau J,Marteau P,Pelletier AL,Carbonnel F,Seksik P,Simon M,Flé,jou JF,Colombel JF,Charlois AL,Roblin X,Nancey S,Bouhnik Y,Berger F,Flourié,B,the GETAID.Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?Gut 2018;67:616-624[PMID:28115492 DOI:10.1136/gutjnl-2016-311892]
101 van den Broek FJ,Stokkers PC,Reitsma JB,Boltjes RP,Ponsioen CY,Fockens P,Dekker E.Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis:Low yield and absence of clinical consequences.Am J Gastroenterol 2014;109:715-722[PMID:21427710 DOI:10.1038/ajg.2011.93]
102 Navaneethan U,Kochhar G,Venkatesh PG,Bennett AE,Rizk M,Shen B,Kiran RP.Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis.J Crohns Colitis 2013;7:974-981[PMID:23523416 DOI:10.1016/j.crohns.2013.02.009]
103 Tabibian JH,Ali AH,Lindor KD.Primary Sclerosing Cholangitis,Part 2:Cancer Risk,Prevention,and Surveillance.Gastroenterol Hepatol(NY)2018;14:427-432[PMID:30166959 DOI:10.6000/1927-7229.2012.01.01.7]